Department of Finemechanics, Graduate School of Engineering, Tohoku University, 6-6-01 Aramaki, Aoba-ku, Sendai 980-8579, Japan.
Division of Clinical Cell Therapy, United Centers for Advanced Research and Translational Medicine (ART), Tohoku University Graduate School of Medicine, 2-1 Seiryo, Aoba-ku, Sendai 980-8575, Japan.
Adv Drug Deliv Rev. 2018 Mar 15;128:148-157. doi: 10.1016/j.addr.2017.07.002. Epub 2017 Jul 6.
Retinal degenerative diseases are a leading cause of irreversible blindness and visual impairment, affecting millions of people worldwide. Although intravitreal injection can directly deliver drugs to the posterior segment of the eye, it is invasive and associated with serious side effects. The design of drug delivery systems targeting the posterior segment of the eye in a less invasive manner has still been challenging because of various anatomical and physiological barriers. In this review, we provide an overview of the current implant device-based approaches used for treating retinal degenerative diseases. We then offer our perspectives on future directions and challenges that remain for developing more effective device-based therapies for retinal diseases.
视网膜退行性疾病是导致不可逆性失明和视力损害的主要原因，影响着全球数以百万计的人。虽然玻璃体内注射可以将药物直接递送到眼球后部，但它具有侵入性，并伴随着严重的副作用。由于各种解剖学和生理学屏障的存在，以较小的侵入性方式设计针对眼球后部的药物递送系统仍然具有挑战性。在这篇综述中，我们概述了目前用于治疗视网膜退行性疾病的基于植入装置的方法。然后，我们提出了对未来发展更有效的基于装置的视网膜疾病疗法的方向和挑战的看法。
